Nectar Lifescience Ltd (NECLIFE) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 216478, "name": "Nectar Lifesci.", "stock_name": "Nectar Lifesci.", "full_name": "Nectar Lifescience Ltd", "name_url": "stocks-analysis/nectar-lifesci", "exchange": 0, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "11.50", "chg": "0.00", "chgp": "0.00%", "dir": 0, "prev_price": "11.50", "mcapval": "224.00 Cr", "mcap": "Micro Cap", "scripcode": 532649, "symbol": "NECLIFE", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "sector_id": 65, "indexname": "India SENSEX", "isin": "INE023H01027", "curr_date": "Jun 19, 03:30 PM", "curr_time": "00:56 AM", "last_traded_at": "Jun 19, 03:30 PM IST", "bse_nse_vol": "1.43 lacs", "exc_status": "Active", "traded_date": "Jun 19, 2026", "traded_date_str": "2026 06 19", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/nectar-lifesci-216478-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Nectar Lifescience Declines 3.78% Amid Mounting Losses and Margin Pressures", "link": "https://www.marketsmojo.com/news/stocks-in-action/nectar-lifescience-declines-378-amid-mounting-losses-and-margin-pressures-4053114", "imagepath": "", "date": "2026-06-14 15:00:47", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>1 June:</strong> Q4 FY26 results reveal deepening operational losses</p>\n <p><strong>2 June:</strong> Flat quarterly performance reported amidst margin pressures</p>\n <p><strong>5 June:</strong> Week closes at Rs.11.96, down 3.78%</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.12.21</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.11.96</div><div class=\"stat-change negative\">-3.78%</div></div>\n <div class=\"stat-item\"><div cla..." }, { "title": "Nectar Lifescience Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/nectar-lifescience-ltd-is-rated-strong-sell-4046505", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/NectarLifescien_mojoScore_4046505.png", "date": "2026-06-11 10:10:22", "description": "Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 11 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance." }, { "title": "Nectar Lifescience Ltd Reports Flat Quarterly Performance Amidst Margin Pressures", "link": "https://www.marketsmojo.com/news/stocks-in-action/nectar-lifescience-ltd-reports-flat-quarterly-performance-amidst-margin-pressures-4030802", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/NectarLifescien_fintrenddot_4030802.png", "date": "2026-06-02 11:00:11", "description": "Nectar Lifescience Ltd reported a flat financial performance for the quarter ended March 2026, marking a notable improvement from previous negative trends but still reflecting significant operational challenges. Despite a stabilisation in revenue growth, the company’s profitability metrics deteriorated sharply, underscoring persistent margin pressures in a competitive pharmaceutical sector." }, { "title": "Are Nectar Lifescience Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-nectar-lifescience-ltd-latest-results-good-or-bad-4028007", "imagepath": "", "date": "2026-06-01 19:23:49", "description": "Nectar Lifescience Ltd's latest financial results for Q4 FY26 reveal significant operational challenges and a concerning financial trajectory. The company reported a consolidated net loss of ₹67.92 crores, which marks a substantial deterioration compared to previous periods. Standalone results also reflect a net loss of ₹37.21 crores, a stark contrast to a profit of ₹0.30 crores in the prior quarter, indicating a severe decline in profitability.\n\nRevenue generation remains critically low, with standalone revenue reported at just ₹1.29 crores, showing minimal recovery from the previous quarter's ₹0.00 crores. This erratic revenue pattern raises questions about the company's operational stability and market demand for its products. The operating profit before depreciation, interest, and tax (PBDIT) fell to a record loss of ₹57.24 crores, illustrating a complete operational breakdown.\n\nThe company’s financial ..." }, { "title": "Nectar Lifescience Q4 FY26: Mounting Losses Signal Deepening Operational Crisis", "link": "https://www.marketsmojo.com/news/result-analysis/nectar-lifescience-q4-fy26-mounting-losses-signal-deepening-operational-crisis-4026922", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/NectarLifescien_quaterlyResult_4026922.png", "date": "2026-06-01 13:03:14", "description": "Nectar Lifescience Ltd., a micro-cap pharmaceutical company specialising in cephalosporins, reported a devastating quarter-on-quarter deterioration in Q4 FY26, with consolidated net losses ballooning to ₹67.92 crores—a staggering 575.96% increase from the previous quarter's ₹14.27 crore profit. The company's standalone net loss stood at ₹37.21 crores, marking a catastrophic reversal from operational stability and raising serious questions about the viability of its business model." }, { "title": "Nectar Lifescience Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/nectar-lifescience-ltd-is-rated-strong-sell-4019994", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/NectarLifescien_mojoScore_4019994.png", "date": "2026-05-29 10:10:22", "description": "Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 08 Jul 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 29 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance." }, { "title": "When is the next results date for Nectar Lifescience Ltd?", "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-nectar-lifescience-ltd-4015096", "imagepath": "", "date": "2026-05-26 23:18:27", "description": "The next results date for Nectar Lifescience Ltd is scheduled for 30 May 2026...." }, { "title": "Nectar Lifescience Ltd Locks at Lower Circuit With 5% Loss — Sellers Queue, No Buyers in Sight", "link": "https://www.marketsmojo.com/news/stocks-in-action/nectar-lifescience-ltd-hits-lower-circuit-amid-heavy-selling-pressure-3998637", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/NectarLifescien_stocks_hitting_lower_circuit_3998637.png", "date": "2026-05-19 10:00:07", "description": "At Rs 11.77, sellers were still queuing — but there were no buyers willing to take the other side. Nectar Lifescience Ltd locked at its lower circuit of 5% on 18 May 2026, with unfilled sell orders and a frozen price, signalling a pronounced imbalance in supply and demand." }, { "title": "Nectar Lifescience Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/nectar-lifescience-ltd-is-rated-strong-sell-3996767", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/NectarLifescien_mojoScore_3996767.png", "date": "2026-05-18 10:10:16", "description": "Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 Jul 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 18 May 2026, providing investors with an up-to-date view of the company’s performance and outlook." } ], "total": 624, "sid": "216478", "stock_news_url": "https://www.marketsmojo.com/news/nectar-lifescience-216478" }, "announcements": [ { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "16-Jun-2026", "details": "Please find attached herewith copy of newspaper publication as per Section 124(6) of Companies Act 2013", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "01-Jun-2026", "details": "Please find attached herewith the copy of newspapers for publication of financial results of the Company for the quarter and financial year ended on March 31 2026", "source": "BSE" }, { "caption": "Financial Results For The Year 2025-26", "datetime": "30-May-2026", "details": "Financial Results for the Year 2025-26", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Nectar Lifescience Ltd has declared <strong>5%</strong> dividend, ex-date: 11 Sep 20", "dt": "2020-09-11", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "", "data": [ { "txt": "Nectar Lifescience Ltd has announced <strong>1:10</strong> stock split, ex-date: 12 Nov 08", "dt": "2008-11-12", "middle_text": "Split" } ] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

1 June: Q4 FY26 results reveal deepening operational losses

2 June: Flat quarterly performance reported amidst margin pressures

5 June: Week closes at Rs.11.96, down 3.78%

Read full news article

Nectar Lifescience Ltd is Rated Strong Sell

2026-06-11 10:10:22

Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 11 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Nectar Lifescience Ltd Reports Flat Quarterly Performance Amidst Margin Pressures

2026-06-02 11:00:11

Nectar Lifescience Ltd reported a flat financial performance for the quarter ended March 2026, marking a notable improvement from previous negative trends but still reflecting significant operational challenges. Despite a stabilisation in revenue growth, the company’s profitability metrics deteriorated sharply, underscoring persistent margin pressures in a competitive pharmaceutical sector.

Read full news article

Are Nectar Lifescience Ltd latest results good or bad?

2026-06-01 19:23:49

Nectar Lifescience Ltd's latest financial results for Q4 FY26 reveal significant operational challenges and a concerning financial trajectory. The company reported a consolidated net loss of ₹67.92 crores, which marks a substantial deterioration compared to previous periods. Standalone results also reflect a net loss of ₹37.21 crores, a stark contrast to a profit of ₹0.30 crores in the prior quarter, indicating a severe decline in profitability. Revenue generation remains critically low, with standalone revenue reported at just ₹1.29 crores, showing minimal recovery from the previous quarter's ₹0.00 crores. This erratic revenue pattern raises questions about the company's operational stability and market demand for its products. The operating profit before depreciation, interest, and tax (PBDIT) fell to a record loss of ₹57.24 crores, illustrating a complete operational breakdown. The company’s financial ...

Read full news article

Nectar Lifescience Q4 FY26: Mounting Losses Signal Deepening Operational Crisis

2026-06-01 13:03:14

Nectar Lifescience Ltd., a micro-cap pharmaceutical company specialising in cephalosporins, reported a devastating quarter-on-quarter deterioration in Q4 FY26, with consolidated net losses ballooning to ₹67.92 crores—a staggering 575.96% increase from the previous quarter's ₹14.27 crore profit. The company's standalone net loss stood at ₹37.21 crores, marking a catastrophic reversal from operational stability and raising serious questions about the viability of its business model.

Read full news article

Nectar Lifescience Ltd is Rated Strong Sell

2026-05-29 10:10:22

Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 08 Jul 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 29 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

When is the next results date for Nectar Lifescience Ltd?

2026-05-26 23:18:27

The next results date for Nectar Lifescience Ltd is scheduled for 30 May 2026....

Read full news article

Nectar Lifescience Ltd Locks at Lower Circuit With 5% Loss — Sellers Queue, No Buyers in Sight

2026-05-19 10:00:07

At Rs 11.77, sellers were still queuing — but there were no buyers willing to take the other side. Nectar Lifescience Ltd locked at its lower circuit of 5% on 18 May 2026, with unfilled sell orders and a frozen price, signalling a pronounced imbalance in supply and demand.

Read full news article

Nectar Lifescience Ltd is Rated Strong Sell

2026-05-18 10:10:16

Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 Jul 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 18 May 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Read full news article